Prevalence of contraindications and prescription of pharmacologic therapies for gout.
about
Review: Gout: A Roadmap to Approaches for Improving Global OutcomesThe efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.2011 recommendations for the diagnosis and management of gout and hyperuricemia.Efficacy and safety of ozonated autohemotherapy in patients with hyperuricemia and gout: A phase I pilot study.Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney diseaseMechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.An old disease with new insights: Update on diagnosis and treatment of gout.Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies.Gout, genetics and ABC transporters.An update on the pathology and clinical management of gouty arthritis.The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.Efficacy of anakinra in gouty arthritis: a retrospective study of 40 casesTrends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009.The challenges of gout management in the elderly.The history and future of probenecid.Gout and its comorbidities: implications for therapy.Emerging therapies for gout.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.Anti-interleukin-1 therapy in the management of gout.Therapeutic approaches to chronic hyperuricemia and gout.Prophylaxis for acute gout flares after initiation of urate-lowering therapy.Pharmacokinetics considerations for gout treatments.Inpatient gout: a review.Hyperuricemia, gout, and cardiovascular disease: an update.Current and future therapies for gout.New and Pipeline Drugs for Gout.Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages.Hyperuricemia and gout in solid-organ transplant: update in pharmacological management.What makes gouty inflammation so variable?Feasibility randomised multicentre, double-blind, double-dummy controlled trial of anakinra, an interleukin-1 receptor antagonist versus intramuscular methylprednisolone for acute gout attacks in patients with chronic kidney disease (ASGARD): protocPEG-ing down (and preventing?) the cause of pegloticase failureComparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks.Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.Treatment of gout: where are we now?
P2860
Q28076018-62B52E43-1F0B-454E-8BE9-C4BEC1003735Q34204854-31C3C534-E302-49C7-BA9F-5601100E33F7Q34250995-2BD800D4-FD45-40EA-8E17-5B47BD225E69Q34292345-B799835B-C2EB-4D35-9B8B-E34902B5B107Q34317722-3B3A0E08-5A90-4BE3-8155-14F921217854Q34322559-533271BF-3EAA-47BC-A8A3-F0B2855C6B28Q34542091-FCFECF21-B48C-44C3-84D3-57EB5AACCCB4Q35012174-9F2229DE-DEB1-4BDF-B071-596FBDB135DCQ35503271-D8F4FDF1-F36F-4B97-8148-CE74FB273EC2Q35508210-F9744FCF-6AD5-4D45-AD8E-80BCC76A980CQ35643985-385F2EFF-177D-4433-B918-5DA8BA67D791Q36779141-6C391182-3A43-412E-8A8F-CF33663B5596Q36870924-7E527AFD-3CC8-4C86-8A52-F79DE3E985F4Q36903272-2E23E936-5C69-42CD-BA77-2051D3E70EBDQ37070180-77ABF273-36ED-49FA-A982-74B5EA541791Q37456247-15A2EE70-05F3-4276-B695-EE062DBAA848Q37690784-30E4FF86-19CD-4379-876A-4F0FA58C81BAQ37691042-BE7A447A-5236-4639-84BC-747BF731D698Q37910891-83908DB1-E314-4726-B51E-65BD561416F8Q37936912-D7DACFEC-AFD2-47B1-9AB3-4A0EC8459511Q38040777-688A21C0-0949-4A58-8CC5-1CFBE91988CDQ38057761-B3BDF9CD-193B-4D9B-8B23-E2DD4D5FC10EQ38123116-EDF774C9-DB21-4B40-9DD3-810C8E8F2670Q38177186-31337C2E-EAFA-4064-B9EF-76478FAD02CAQ38201666-6B666709-300F-4F3F-8447-D64A8EA7EE9FQ38206603-3B1AEF1C-E402-440F-990E-D1CC3E33DE67Q38210284-41C6B547-0CD3-4C0F-AC70-BF44C76697C2Q38258983-D29D93E8-0BA5-4403-9171-7D0D9D50944BQ38367776-02506A90-78A9-4670-B1A5-B140D7415286Q38660829-2954E7A7-B26A-49E1-8999-5DF6421D31D5Q38813045-E1E8EC4B-19AC-403D-B0A2-D49B5D24E1C6Q39278948-41FD36DB-405F-4F91-A602-7D208EB7FE32Q40173526-4DC976C1-1EA2-4113-898E-1ACE9FBB2E61Q40605885-6DE6489D-C24A-4EBF-B7DA-6CBCDA2864D5Q41451121-A535F774-5ADD-4262-A861-9AF69AE8F39DQ41581182-F5C30F43-434F-4544-9A05-B90B6595F7BDQ42699501-C79986D7-E602-4629-A8C3-B062BFD2F8CDQ44396750-E0AA761D-B778-4A10-8CBB-3C0B457C8463Q46708226-C877B6C9-F8EF-41CA-96E9-3968409ED2ADQ49616087-A4DF86D8-A403-435A-B4D6-FDAE6A5954EF
P2860
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
@en
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
@nl
type
label
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
@en
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
@nl
prefLabel
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
@en
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
@nl
P2093
P1476
Prevalence of contraindications and prescription of pharmacologic therapies for gout.
@en
P2093
Cheongeun Oh
Daria B Crittenden
Kristen H Lee
Mark C Fisher
Robert T Keenan
Svetlana Krasnokutsky
William R O'Brien
P304
P356
10.1016/J.AMJMED.2010.09.012
P407
P577
2011-02-01T00:00:00Z